臺灣健保預檢規則實作指引
0.0.1 - CI Build
臺灣健保預檢規則實作指引
0.0.1 - CI Build
臺灣健保預檢規則實作指引, published by Example Publisher. This guide is not an authorized publication; it is the continuous build for version 0.0.1 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/TWNHIFHIR/cql/ and changes regularly. See the Directory of published versions
以下為本IG之Libraries。
Pertuzumab與Trastuzumab皮下注射複方製劑給付規定(早期乳癌)-PertuzumabTrastuzumabSC Rule1
Pertuzumab與Trastuzumab皮下注射複方製劑給付規定(移轉性乳癌)-PertuzumabTrastuzumabSC Rule2
Trastuzumab Deruxtecan(早期乳癌_二線治療)給付規定-Trastuzumab Deruxtecan Rule1
Trastuzumab Deruxtecan(轉移性乳癌)給付規定-Trastuzumab Deruxtecan Rule2
Atezolizumab、Durvalumab給付規定(小細胞肺癌)-LC Atezolizumab、Durvalumab Rule1
Dabrafenib、Trametinib給付規定(非小細胞肺癌)-LC Dabrafenib、Trametinib Rule1
Pembrolizumab、Atezolizumab給付規定(鱗狀、非鱗狀非小細胞肺癌第一線用藥(單用))-LC Pembrolizumab、Atezolizumab Rule1
Pembrolizumab、Atezolizumab給付規定(非鱗狀非小細胞肺癌第一線用藥(併用))-LC Pembrolizumab、Atezolizumab Rule1
Darolutamide給付規定（與docetaxel併用於治療高風險轉移性的去勢敏感性前列腺癌(mCSPC)）-PC Darolutamide Rule1
Darolutamide給付規定（治療高風險非轉移性去勢抗性前列腺癌(high risk nmCRPC)的成年男性）-PC Darolutamide Rule2
Enzalutamide給付規定（高風險非轉移性去勢抗性前列腺癌(high risk nmCRPC)）-PC Enzalutamide Rule1
Enzalutamide給付規定（高風險轉移性的去勢敏感性前列腺癌(mCSPC)）-PC Enzalutamide Rule2
Enzalutamide給付規定（藥物或手術去勢抗性的轉移性前列腺癌(mCRPC)-未化療）-PC Enzalutamide Rule3
Enzalutamide給付規定（藥物或手術去勢抗性的轉移性前列腺癌(mCRPC)-已化療）-PC Enzalutamide Rule4